

## FREQUENTLY ASKED QUESTIONS

# MONOCLONAL GAMMOPATHY SCREENING AND MONITORING

**Q** What is the turn around time for the screening and monitoring tests using the MALDI-TOF MS assay?

**A** The turn around time for this testing is 1-2 days.

**Q** What can this testing detect?

**A** Research performed at Mayo Clinic has shown this testing to be effective for the detection of

- AL-amyloidosis risk factors - through the detection of glycosolated light chains
- M-protein spike -Mass-FIX technology is ~10X more sensitive and specific than traditional testing methods
- Early identification of myeloma relapse
- Accurate monitoring of patients with MGUS
- Differentiation of the IgG Kappa mass from monoclonal therapeutics or patient residual disease in > 80 percent of cases.
- Identification of IgG4 lymphoproliferative disease through the accurate detection of the 4:1 Kappa:Lambda ratio

**Q** Can I use this testing on patients receiving a monoclonal therapy?

**A** Yes, monitoring of patients on monoclonal therapies can be performed accurately using this testing. In many patient cases, weighing of the proteins allows for segregation of a patient's M-spike from the interference of a monoclonal therapy.

**Q** Does this testing replace the need for bone marrow procedures?

**A** We will continue to need to test bone marrow, but if this blood test shows residual disease, there will be no point in performing a bone marrow test at that time.

**Q** Does this testing replace MRD testing currently available on bone marrow specimens?

**A** No, while the MASS-FIX technology is more sensitive and specific assessing a patients response for MRD assessment and most clinical trials requires a detection level to  $10^{-5}$  on a bone marrow sample.  
(Mayo Test ID: MRDMM)

**Q** Can I perform this testing at my facility?

**A** Currently Mayo Clinic is the only laboratory offering this patented testing. Please contact 1-800-533-1710 and speak with a Mayo Clinic Laboratories representative